Chronic hives (chronic urticaria) clinical trials
Medical name: Chronic urticaria · Skin
52 trials are recruiting, according to ClinicalTrials.gov.
Checked against the registry on 5 October 2026. Listing a trial here is not a recommendation; taking part is voluntary and each study team decides who is eligible.
An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria
Ages 18 Years to 65 Years · 3 sites · ARS Pharmaceuticals, Inc.
Details and how to check if you qualify · NCT06927999 on ClinicalTrials.gov
Apremilast Added to Antihistamines in Chronic Urticaria
Ages 18 Years to 65 Years · 1 site · Rashid Latif Medical College
A Phase 2 Study of MG-K10 in Chronic Spontaneous Urticaria
Ages 18 Years to 75 Years · 0 sites · Shanghai Mabgeek Biotech.Co.Ltd
Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks
Ages 18 Years to no maximum · 1 site · Novartis Pharmaceuticals
A Study of Efficacy and Safety of TLL-018 in CSU Participants With Inadequate Response to 2nd-generation H1-AHs
Ages 18 Years to 75 Years · 0 sites · Hangzhou Highlightll Pharmaceutical Co., Ltd
A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU)
Ages 18 Years to 85 Years · 0 sites · Calixis Inc.
A Randomised Controlled Trial of ePROM-Guided Flexible Scheduling in Dermatology
Ages 16 Years to no maximum · 0 sites · National University Hospital, Singapore
A Phase Ib/IIa Study Assessing the Rapid Onset Characteristics of TLL-018 for Moderate-to-Severe CSU With Inadequate Response to Second-Generation H1 Antihistamines
Ages 18 Years to 75 Years · 1 site · Hangzhou Highlightll Pharmaceutical Co., Ltd
Remibrutinib in Real-world Clinical Practice - a Germany Sub-study (REASSERT)
Ages 18 Years to no maximum · 1 site · Novartis Pharmaceuticals
A Trial of HRS-3095 in Healthy Volunteers
Ages 18 Years to 55 Years · 1 site · Atridia Pty Ltd.
Phase Ib, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study of Alpha-0261 Tablets to Assess Safety and Tolerability in Patients With Chronic Spontaneous Urcaria (Part 1) and Food Effect in Healthy Adults (Part 2).
Ages 18 Years to 75 Years · 1 site · AlphaMol Science Ltd. (Shanghai)
Trial to Test the Efficacy of Using Magnetic Fields to Stimulate the Back to Treat Chronic Lower Back Pain.
Ages 18 Years to 64 Years · 1 site · Joe X. Zhang
A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria
Ages 18 Years to 70 Years · 2 sites · Chengdu Suncadia Medicine Co., Ltd.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU)
Ages 18 Years to 75 Years · 10 sites · Bambusa Therapeutics
A Prospective, Single-centre, Observational Cohort Study on the Efficacy and Safety of Bacterial Lysate (OM-85) in Combination With Antihistamines for the Treatment of Chronic Spontaneous Urticaria (CSU)
Ages 18 Years to 65 Years · 1 site · The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Autologous Whole Blood Therapy in Chronic Idiopathic Urticaria Patients.
Ages 18 Years to no maximum · 1 site · Cairo University
A Study of MG-K10 in Chronic Spontaneous Urticaria
Ages 12 Years to 75 Years · 0 sites · Shanghai Mabgeek Biotech.Co.Ltd
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults
Ages 18 Years to 65 Years · 1 site · Enanta Pharmaceuticals, Inc
Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines
Ages 18 Years to 75 Years · 30 sites · Yuhan Corporation
Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.
Ages 18 Years to no maximum · 1 site · Jemincare
Circadian Rhythm Deregulation in Patients With CAPS
Ages 6 Years to no maximum · 6 sites · Hospices Civils de Lyon
Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria
Ages 18 Years to 75 Years · 30 sites · Beijing InnoCare Pharma Tech Co., Ltd.
Remibrutinib in Real-world Clinical Practice
Ages 18 Years to no maximum · 1 site · Novartis Pharmaceuticals
Remibrutinib in Real-world Clinical Practice - a US Sub-study
Ages 18 Years to 100 Years · 1 site · Novartis Pharmaceuticals
A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients
Ages 18 Years to 100 Years · 1 site · Novartis Pharmaceuticals
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
Ages 18 Years to no maximum · 72 sites · Celldex Therapeutics
Effects of Diet and Oxidative Stress on Disease Severity and Response to Omalizumab in Chronic Spontaneous Urticaria
Ages 18 Years to 65 Years · 1 site · Istanbul Training and Research Hospital
Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)
Ages 18 Years to 75 Years · 1 site · Keymed Biosciences Co.Ltd
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
Ages 18 Years to no maximum · 131 sites · Celldex Therapeutics
Pseudoallergen-Free and Low-Histamine Diet in Adolescents With Chronic Spontaneous Urticaria
Ages 1 Year to 18 Years · 1 site · Istanbul University
Mediterranean and Low-Histamine Diets for Pediatric Chronic Spontaneous Urticaria
Ages 12 Years to 18 Years · 1 site · Saglik Bilimleri Universitesi
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
Ages 18 Years to no maximum · 69 sites · Pfizer
A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible Urticaria
Ages 18 Years to 75 Years · 2 sites · Granular Therapeutics Limited
ROLL'YN-OMA: an Observational Study in Patients Treated by Omlyclo®, an Omalizumab Biosimilar
Ages 18 Years to no maximum · 1 site · Celltrion HealthCare France
Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load
Ages 18 Years to 120 Years · 1 site · National Institute of Allergy and Infectious Diseases (NIAID)
SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
Ages 18 Years to no maximum · 8 sites · Leiden University Medical Center
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants
Ages 18 Years to 70 Years · 1 site · BeOne Medicines
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
Ages 18 Years to no maximum · 9 sites · Novartis Pharmaceuticals
Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria
Ages 18 Years to no maximum · 14 sites · Novartis Pharmaceuticals
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Spontaneous Urticaria.
Ages 18 Years to 65 Years · 1 site · Jiangsu Hansoh Pharmaceutical Co., Ltd.
Ilaris NIS in Korea
Ages 2 Years to 100 Years · 1 site · Novartis Pharmaceuticals
Interleukin-2 for Refractory Chronic Spontaneous Urticaria
Ages 18 Years to 74 Years · 1 site · Second Xiangya Hospital of Central South University
Treatment Options for Chronic Urticaria
Ages 13 Years to 60 Years · 1 site · Sheikh Zayed Medical College
Deep Phenotyping of CIndU
Ages 18 Years to no maximum · 2 sites · Centre for Human Drug Research, Netherlands
Analysis of the Role of IgE Proteoforms in Health and Disease
Ages 18 Years to no maximum · 1 site · KU Leuven
Trial of JYB1904 in Chronic Spontaneous Urticaria.
Ages 18 Years to no maximum · 1 site · Jemincare
Extending Omalizumab Treatment Intervals in Patients With Chronic Spontaneous Urticaria
Ages 18 Years to no maximum · 1 site · Simon Francis Thomsen
Are Mast Cells Involved in Autoinflammatory Diseases
Ages 18 Years to no maximum · 1 site · Assistance Publique - Hôpitaux de Paris
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Ages 18 Years to no maximum · 18 sites · Cogent Biosciences, Inc.
Deployment o the Multidisciplinary Prospective Cohort Imminent
Ages 18 Years to no maximum · 1 site · University Hospital, Lille
Characteristics and Management of Patients With Severe Chronic Spontaneous and/or Inducible Urticaria Refractory to Optimized Omalizumab Treatment: A French Multicenter Observational Study.
Ages 18 Years to 80 Years · 1 site · Centre Hospitalier Universitaire de Besancon
Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases)
Ages No minimum to 99 Years · 1 site · National Institute of Allergy and Infectious Diseases (NIAID)
More: Acne clinical trials · Alzheimer’s disease and related dementias clinical trials · Cannabis use disorder clinical trials · COPD (chronic obstructive pulmonary disease) clinical trials · Depression (major depressive disorder) clinical trials · Moderately to severely active crohn's disease clinical trials
